Pharmaceuticals
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. clinical sites RHB-...
2020-11-20 21:00
5388
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely de...
2020-11-20 21:00
5741
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December
SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, today announced that data from its global multiple myeloma program will be presented, including two oral presentations and one poster session, at the 62nd American Society of Hematology (ASH)...
2020-11-20 19:00
3426
Zuellig Pharma expands cold storage warehouse capacity across key markets in Asia in preparation for COVID-19 vaccine
SINGAPORE, Nov. 20, 2020 /PRNewswire/ -- Zuellig Pharma, a leading healthcare services provider inAsia, announced that it will significantly expand its cold storage warehouse capacity in key regional markets over the next 12 months. As the largest vaccines and cold chain pharmaceutical distributo...
2020-11-20 15:31
6116
Qiming's Portfolio Company Antengene Lists on Main Board of HKEX
SHANGHAI, Nov. 20, 2020 /PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price isHK$18.08 per share; the stock opens at HK$ 19.6 per share, up 8.41%, with a market cap of HK$ 13.097 bi...
2020-11-20 14:22
6441
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease
FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects The Phase 2/3 study is designed to evaluate outpatient-b...
2020-11-20 07:00
3285
Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology
Summarizes ciraparantag's expected mechanism of action, pharmacokinetic, and pharmacodynamic characteristics and its proof of concept as an anticoagulant reversal agent LUXEMBOURG and ZUG, Switzerland, Nov. 20, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") today announced that data demonst...
2020-11-20 01:26
2014
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Nov. 19, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merg...
2020-11-19 21:09
9143
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia Enrollment in the 270-patient global Phase 2/3 COVID-19 study with opaganib is more than 50% complete ...
2020-11-19 20:21
4745
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr.Mark Eccleston, a founding sci...
2020-11-19 20:00
7403
CUHK Microbiome Immunity Formula Hastens Recovery of COVID-19 Patients and Offers Hope to Boost Immunity
HONG KONG, Nov. 19, 2020 /PRNewswire/ -- Gut microbiota plays an important role in regulating immunity against infections. People who suffer from imbalance in gut microbiota (dysbiosis) are more susceptible to viral infection and other complications. An earlier study by the Faculty of Medicine of...
2020-11-19 17:13
3532
With Elekta Studio, Elekta brings complete image-guided brachytherapy workflow to a single room
VEENENDAAL, The Netherlands, Nov. 19, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) today introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including ap...
2020-11-19 15:16
4261
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
SHANGHAI and SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial inChina. The tr...
2020-11-19 08:30
3118
INEX Innovate's iGene Laboratory announces new personalised medicine genotyping analysis project with Eli Lilly and Company's research unit Lilly Centre for Clinical Pharmacology
SINGAPORE, Nov. 19, 2020 /PRNewswire/ -- INEX Innovate's iGene Laboratory (iGene) announced today a project withEli Lilly and Company's (NYSE: LLY) research unitLilly Centre for Clinical Pharmacology (LCCP), which conducts early phase clinical trials in healthy participants and patients inSingapo...
2020-11-19 08:00
3170
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled - on track to e...
2020-11-19 07:00
2824
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon,South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing ...
2020-11-18 20:00
1776
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that the board of directors of the Company (the "Board") resolved to change the use of the remaining Net Proceeds from the Global Offering. (see announcement: https://www....
2020-11-18 17:00
7008
Cipla launches 'Covi-G' for COVID-19 rapid antibody detection
MUMBAI, India, Nov. 18, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") today announced that it signed a licensing agreement with aBelgium-based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test kit, across most Emergin...
2020-11-18 16:36
3896
Regent Pacific Announces Important Commercialisation Progress On FORTACIN(TM) / SENSTEND(TM)
MAINLAND CHINA * Regent Pacific to receive a total payment of US$4 million upon the receipt of approval from the National Medical Products Administration (NMPA) for conducting human trial * China is expected to be the single largest market for Sendstend™ UNITED STATES * The Phase II valid...
2020-11-17 22:09
3545
Russia is considered a highly trusted vaccine manufacturer and almost half of respondents in 11 countries are aware of Sputnik V, a YouGov poll shows
MOSCOW, Nov. 17, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), announces the results of a survey of more than 12,000 respondents in 11 countries on their attitude towards vaccination against coronavirus and their vaccine preferences. According to ...
2020-11-17 21:38
1202
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
